Research has shown that the combination of dabrafenib and trametinib demonstrates meaningful efficacy in various BRAF-positive tumor types, such as NSCLC, melanoma, and ATC, and among patients with some rare cancers that lack other treatment options. Here, BRAF is linked to non-small cell lung carcinoma.